> Detailanzeige

Huang, Richard S. P.; Severson, Eric; Haberberger, James; Duncan, Daniel L.; Hemmerich, Amanda; Edgerly, Claire; Ferguson, N. Lynn; Frampton, Garrett; Owens, Clarence; Williams, Erik; Elvin, Julia; Vergilio, Jo-Anne; Killian, Jonathan Keith; Lin, Douglas; Morley, Samantha; McEwan, Deborah; Holmes, Oliver; Danziger, Natalie; Cohen, Michael B.; Sathyan, Pratheesh; McGregor, Kimberly; Reddy, Prasanth; Venstrom, Jeffrey; Anhorn, Rachel; [...]

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry
  • Beteiligte: Huang, Richard S. P.; Severson, Eric; Haberberger, James; Duncan, Daniel L.; Hemmerich, Amanda; Edgerly, Claire; Ferguson, N. Lynn; Frampton, Garrett; Owens, Clarence; Williams, Erik; Elvin, Julia; Vergilio, Jo-Anne; Killian, Jonathan Keith; Lin, Douglas; Morley, Samantha; McEwan, Deborah; Holmes, Oliver; Danziger, Natalie; Cohen, Michael B.; Sathyan, Pratheesh; McGregor, Kimberly; Reddy, Prasanth; Venstrom, Jeffrey; Anhorn, Rachel; [...]
  • Erschienen: Frontiers Media SA, 2021
  • Erschienen in: Pathology and Oncology Research
  • Sprache: Nicht zu entscheiden
  • DOI: 10.3389/pore.2021.592997
  • ISSN: 1532-2807
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>Comprehensive genomic profiling (CGP) and immunohistochemistry (IHC) are important biomarker tools used for patients with non-small cell lung cancer (NSCLC) given the expanding number of standard-of-care therapies that require companion diagnostic testing. We examined 9450 NSCLC real-world patient samples that underwent both CGP and programmed death-ligand 1 (PD-L1) IHC to understand the biomarker landscape in this patient cohort. By assessing National Comprehensive Cancer Network (NCCN)-recommended biomarkers including genomic alterations, tumor mutational burden (≥10 mutations/Mb cut-off), and PD-L1 expression (Tumor Proportion Score (TPS) ≥ 50% cut-off), we show that CGP + PD-L1 IHC yielded potentially actionable results for 70.5% of the 9,450 patients with NSCLC. Among the remaining 29.5% (2,789/9,450) of patients, 86.7% (2,419/2,789) were potentially eligible for another biomarker-associated therapy and/or clinical trial based on their genomic profile. In addition, in the PD-L1<jats:sup>TPS≥50%</jats:sup> disease subset, <jats:italic>BRAF</jats:italic> mutations, <jats:italic>MET</jats:italic> mutations, <jats:italic>MET</jats:italic> amplifications, and <jats:italic>KRAS</jats:italic> mutations were significantly enriched; and in the PD-L1<jats:sup>TPS&amp;lt;50%</jats:sup>, <jats:italic>EGFR</jats:italic> mutations, <jats:italic>ERBB2</jats:italic> mutations, <jats:italic>STK11</jats:italic> mutations, and <jats:italic>KEAP1</jats:italic> mutations were enriched. These findings highlight the improved clinical utility of combining CGP with IHC to expand the biomarker-guided therapeutic options available for patients with NSCLC, relative to single biomarker testing alone.</jats:p>
  • Zugangsstatus: Freier Zugang